A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.
about
Maraviroc: a review of its use in HIV infection and beyondAntiretroviral therapy response among HIV-2 infected patients: a systematic reviewEvolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.First-year lymphocyte T CD4+ response to antiretroviral therapy according to the HIV type in the IeDEA West Africa collaborationGenotypic resistance profiles of HIV-2-treated patients in West Africa.HIV-2 integrase variation in integrase inhibitor-naïve adults in Senegal, West Africa.Zidovudine and Lamivudine for HIV Infection.Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.Characteristics of HIV-2 and HIV-1/HIV-2 Dually Seropositive Adults in West Africa Presenting for Care and Antiretroviral Therapy: The IeDEA-West Africa HIV-2 Cohort Study.Update on human immunodeficiency virus (HIV)-2 infection.An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.Wide Variations in Compliance with Tuberculosis Screening Guidelines and Tuberculosis Incidence between Antiretroviral Therapy Facilities - Côte d'Ivoire.Male Circumcision and the Epidemic Emergence of HIV-2 in West Africa.Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra.Immunologic response in treatment-naïve HIV-2-infected patients: the IeDEA West Africa cohort.Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West AfricaComplex patterns of protease inhibitor resistance among antiretroviral treatment-experienced HIV-2 patients from Senegal: implications for second-line therapy.Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1.Trends of HIV-1, HIV-2 and dual infection in women attending outpatient clinics in Senegal, 1990-2009.An underestimated lentivirus model: what can HIV-2 research contribute to the development of an effective HIV-1 vaccine?Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Emerging infections of the central nervous system.MK-8591 (4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine) Exhibits Potent Activity against HIV-2 Isolates and Drug-Resistant HIV-2 Mutants in Culture.Mortality and survival patterns of people living with HIV-2Effect of sex and age on outcomes among HIV-2-infected patients starting antiretroviral therapy in West Africa.Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test.Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.First line raltegravir/emtricitabine/tenofovir combination in HIV-2 infection: phase 2 non-comparative trial (ANRS 159 HIV-2).p24 revisited: a landscape review of antigen detection for early HIV diagnosis
P2860
Q26778504-DB3E029C-CC52-4FFB-BA4E-9E92936DC4BFQ27003854-4B01F1F2-D2AA-4DF2-9F00-FC86AE3A11D1Q33591409-7ACCFEDF-0BE5-4667-929D-340746AD3EB0Q33891896-CE8F9F0B-6994-4976-BB14-E34927E7D35AQ33954546-E6F7A4BD-8E1F-45F7-8F83-47EE6ADBDCA0Q33963958-2BA07366-4470-4651-BEFA-251968623675Q34194561-11C09AB3-E072-49DB-8435-E5E75342DBAFQ34329544-249638AE-0D08-4DC8-9E38-EBFC5959570DQ34793224-CD2133EE-7335-46E1-B00A-EC67200A96CAQ35019924-A385BC1D-B68F-4519-AAD6-B87DDB88EFFDQ35273824-7AEF14B4-40D1-4709-8824-A5E633618FBDQ36044825-C4D79584-EF3E-4BF1-B67A-22B8BCAEAC84Q36214981-9CDB688C-84E1-4E61-BBD9-9F5C9B069315Q36239297-E22075C4-A5EB-4A40-932A-6909173FAE4AQ36371387-5B1B7272-EC88-4E36-BC1E-73DB9C25C1E1Q36564668-8BC00924-8D65-427A-B25B-21A7754A5F03Q36897863-790EE706-3FEE-4B09-BF57-A547AB19F5C0Q37026564-B79263C2-1B74-4166-8022-14103515F914Q37053007-481ACC6B-F39C-43B7-9363-8786A96F892AQ37053015-55BCF154-8DF5-4CF4-9CC3-411D475B7E58Q37845847-BAF45697-E20F-4A98-835A-CF71766BA3A4Q37859395-C4CCC49D-F3B8-4138-B7AA-C3B4E64A4060Q38153635-B7BEFF66-7050-43AC-85AF-C9B70C9B79EAQ38755690-28CA2424-4670-4D01-A09F-A0AF6B22F9E3Q38851677-CBAA2E0F-E991-46E5-AD48-BC4E09162227Q40485909-B4158D5E-7BBB-417D-A0ED-72B0CFDFE351Q44990505-B5195963-1E88-4055-876E-3B62A8FB8F01Q46590840-D7ED55C7-6580-4F41-AFDA-03B0E3A57139Q47560712-59C7BA0F-1B96-4930-88B8-1F6112940D95Q52625498-96BD4844-E786-4041-AEE1-93DCAEBC3D4DQ57150995-A119E29F-3AC8-47AF-92A5-AAAA261240BB
P2860
A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A call for randomized controll ...... IV-2 infection in West Africa.
@en
A call for randomized controll ...... IV-2 infection in West Africa.
@nl
type
label
A call for randomized controll ...... IV-2 infection in West Africa.
@en
A call for randomized controll ...... IV-2 infection in West Africa.
@nl
prefLabel
A call for randomized controll ...... IV-2 infection in West Africa.
@en
A call for randomized controll ...... IV-2 infection in West Africa.
@nl
P2093
P2860
P921
P1433
P1476
A call for randomized controll ...... IV-2 infection in West Africa.
@en
P2093
Hilton C Whittle
John N Nkengasong
Papa Salif Sow
Sabelle Jallow
Sarah Rowland-Jones
Serge-Paul Eholié
P2860
P304
2069-72; discussion 2073-4
P356
10.1097/QAD.0B013E32830EDD44
P407
P577
2008-10-01T00:00:00Z